Form D · Biotechnology
Telesta Therapeutics Inc.
Belleville, A6 · CIK 0001650779
Offering snapshot reported Aug 26, 2015 · SEC filing
- Reported sold
- $26.4M Offering amount: $26.4M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 18, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 26, 2015 | Initial | $26,400,000 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.85M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-246467
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Ladenburg Thalmann & Co. Inc. | 505 | Ladenburg Thalmann & Co. Inc. · CRD 505 |
| Roth Capital Partners, LLC | 15407 | Roth Capital Partners, LLC · CRD 15407 |
Source: Form D, filed Aug 26, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yvon Bastien | Director |
| Michael Joseph Berendt | Director, Executive |
| Mathieu Boudreau | Executive |
| Rod Budd | Director |
| Monique Champagne | Executive |
| Brian Ford | Executive |
| Lyne Fortin | Director |
| Donald Olds | Executive |
| James Rae | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
231 Dundas Street East
Belleville, A6, K8N 1E2
Belleville, A6, K8N 1E2